There is no over-the-counter GLP-1 medicine in the United States. That is checkable rather than a matter of opinion, so we checked it: every drug listing the FDA holds for the seven GLP-1 molecules in its directory, counted by product type on 2026-09-17. The answer was 436 listings and not one over-the-counter product.
What the search is usually really asking is whether something on a shelf does the same job. This page covers both halves: the census, and what the products sold without a prescription actually are. Nothing here is advice about what anyone should use; that belongs with a clinician, as our editorial standards set out.
The census
The FDA's National Drug Code directory records every drug product a company lists with the agency, and classifies each by type. We queried the openFDA NDC endpoint (data last updated 2026-09-16) for each GLP-1 molecule and counted the listings by product type.
| Molecule | Finished prescription drug | Bulk ingredient | Drug for further processing | Human OTC drug |
|---|---|---|---|---|
| Semaglutide | 26 | 86 | 25 | 0 |
| Tirzepatide | 54 | 71 | 42 | 0 |
| Liraglutide | 22 | 40 | — | 0 |
| Dulaglutide | 11 | 2 | 7 | 0 |
| Exenatide | 4 | 9 | — | 0 |
| Orforglipron | 6 | 9 | 21 | 0 |
| Lixisenatide | 1 | — | — | 0 |
| Total | 124 | 217 | 95 | 0 |
A listing is a product-and-package record, not a distinct drug; one brand can hold several. The count is of listings, and what matters is the last column.
The control: the census does find OTC products when they exist
A search that returns zero proves nothing unless the same search can return something. So we ran it on orlistat, a weight-loss drug that has been sold without a prescription for years. It returned 2 human OTC drug listings, both under Alli's application NDA021887, with a marketing start date of 7 February 2007, alongside 3 prescription listings and 7 bulk ingredient listings.
The method finds over-the-counter weight-loss drugs. It finds none for GLP-1s.
What the bulk numbers say
The column that surprises most people is the middle one. Semaglutide has 86 bulk ingredient listings against 26 finished products — more than three to one. A bulk ingredient is the raw active substance, sold to manufacturers and, for listings marked for prescription compounding, to compounding pharmacies.
Those listings are the upstream end of the compounded market. They are not a route to buying the drug without a prescription: a compounded product still legally requires one. The FDA's own concerns about that supply chain are specific enough to have produced an import alert, covered below.
Why these drugs require a prescription
Federal law sets the test in 21 U.S.C. 353(b)(1). A drug must be dispensed only on a prescription if either:
- because of "its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use," it "is not safe for use except under the supervision of a practitioner"; or
- it "is limited by an approved application" to use under a practitioner's supervision.
Every GLP-1 was approved as a prescription drug, so the second limb settles the status of each one. The labels show why a switch would be a large step. Most approved GLP-1 products carry a boxed warning on thyroid C-cell tumours in rodents (Byetta, the twice-daily exenatide, is an exception), and the class carries warnings on pancreatitis, gallbladder disease, kidney injury from dehydration, and hypoglycaemia when combined with insulin or a sulfonylurea. How those warnings are worded, and what the counts behind them are, is on our side-effects hub.
A drug moves from prescription to over-the-counter when a sponsor applies and the FDA approves it, which is what happened with orlistat. No application to switch a GLP-1 is public.
What is sold without a prescription instead
Search a pharmacy shelf or a marketplace for "GLP-1" and three kinds of product come back. None contains a GLP-1 drug.
| Product type | What it contains | What it claims | Our page |
|---|---|---|---|
| Capsule supplements | Botanical extracts such as berberine, plus vitamins and minerals | To encourage the body's own GLP-1 release | Berberine capsules and their trials |
| Probiotic "boosters" | Bacterial strains, often with fibre | To support the gut cells that release GLP-1 | GLP-1 boosters |
| Skin patches | Botanical ingredients on an adhesive | To deliver an ingredient through the skin | GLP-1 patches |
The regulatory difference between these and a medicine is structural. The FDA does not approve dietary supplements for effectiveness before they are sold. A GLP-1 medicine reaches the market only after controlled trials the agency has reviewed.
The best-tested ingredient in the capsule category is berberine, and its largest trial was negative on the outcome it is sold for: 1 g a day for six months in 337 people made no difference to visceral or liver fat. The details, and the one supplement trial that was positive, are on the supplements page. The body's own GLP-1, which all three product types aim to raise, lasts 1.5 to 2 minutes in the blood — the reason that premise is harder than it sounds is on our page about what clears the body's own GLP-1.
Sellers offering the drug itself without a prescription
A separate category sells, or claims to sell, the actual molecule without a prescription, usually as a "research" product or through an online storefront. The FDA's page on unapproved GLP-1 drugs, current as of 1 September 2026, is the primary record here. Among the warning signs it lists for consumers, a company that:
- "does not require a screening and prescription by a licensed doctor before providing medicine"
- "offers medicine at deep discounts or prices that seem too good to be true"
- "makes claims such as the compounded drug is the same as an FDA-approved drug"
- "sends medicine that looks different than what you've previously received"
The same page states that retatrutide and cagrilintide "cannot be used in compounding under federal law", that the agency has warned telehealth companies for marketing retatrutide directly to consumers, and that it has established an import alert (66-80) aimed at GLP-1 active ingredients with potential quality concerns. It also reports fraudulent compounded semaglutide and tirzepatide whose labels name pharmacies that did not make them, or that do not exist.
Under the statute above, a drug dispensed without a required prescription is treated as misbranded while held for sale.
The routes that do exist
Every lawful route to a GLP-1 medicine runs through a prescriber. What differs is price and who pays, and each has its own page:
- Cash price, by brand and channel: our GLP-1 cost hub, with the tablet forms on GLP-1 pills cost.
- Insurance, Medicare and why coverage turns on the indication: GLP-1 insurance coverage.
- Which drugs count as GLP-1s at all, including the older generics: which drugs are GLP-1s.
What this page does not establish
- The census counts listings, not products on sale. A listing can describe a package that is no longer marketed. A zero in the OTC column is still a zero.
- The directory covers products listed with the FDA. An unlisted product sold online would not appear, which is itself one of the warning signs on the FDA's page.
- Other countries set their own rules. This page covers the United States only.
How this was counted
Seven openFDA NDC queries on 2026-09-17, one per molecule, each counting product_type across all listings whose generic name matched; plus the orlistat control query, whose two OTC listings were opened to confirm brand, labeler, application number and start date. The statutory text is 21 U.S.C. 353(b)(1). The FDA consumer page was read the same day.